Back to All Combinations
KRAS G12D + TP53
Intermediate PrognosisGenes Involved
KRAS G12D
TP53
Recommended Treatments
Standard chemotherapy
G12D inhibitors (trials)
Treatments to Avoid
Anti-EGFR therapy
Key Statistics
12.00%
Prevalence in CRC
No
Targetable
Clinical Notes
KRAS G12D is not yet targetable with approved drugs. Clinical trials for G12D inhibitors ongoing.
Information
Category: General
Evidence Level: B
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.